We are studying whether GR1014 gel can help prevent skin damage during radiation therapy for localized breast cancer after lumpectomy. This trial compares the gel to a standard treatment to see which is more effective.
We are evaluating new combinations of immunotherapy for adults with untreated advanced non-small cell lung cancer. The goal is to see if these combinations are safe and more effective than standard treatment.
We are investigating if continuing cemiplimab treatment helps patients with oligometastatic NSCLC live longer without disease progression after initial therapy. This study compares the effects of cemiplimab to a placebo.
We are studying a combination of pembrolizumab and a personalized vaccine for patients with advanced mesothelioma who have not responded to earlier treatments. The goal is to see if this approach can improve outcomes for these patients.
We are testing a new medication, lebrikizumab, for people with chronic rhinosinusitis and nasal polyps who are already using nasal corticosteroids. The study aims to see if it can improve nasal congestion and reduce polyp severity.
We are comparing two approaches to ovarian stimulation in patients preparing for embryo testing. The goal is to see if one method produces more healthy embryos than the other.
We are studying how well oral pantoprazole works for maintaining healing in children and teens aged 1 to 17 with erosive esophagitis. We also want to understand its safety and how well they tolerate the treatment.
We are comparing two sedation methods for very preterm infants on mechanical ventilation to see which one helps with extubation time and overall safety. This study will help us understand the best approach for sedation in these vulnerable patients.
We are comparing two treatment options for low-risk, triple-negative early breast cancer to see which is more effective. The study also evaluates how these treatments affect patients' quality of life.
We are investigating whether apremilast can improve symptoms in patients over 6 years old with epidermolysis bullosa simplex. The study will also look at the safety of the treatment and how it affects quality of life.
We are studying whether discontinuing beta-blockers is as safe for patients with improved heart function as continuing the medication. This trial aims to understand the effects on heart failure relapse and overall heart health.
We are studying the long-term safety of vedolizumab in children with ulcerative colitis or Crohn’s disease. The trial also looks at how this treatment affects their quality of life and related health events.
We are assessing a new anti-cancer treatment, DSB2455, for patients with advanced malignancies. The goal is to understand how well it works when given alone.
We are testing a new treatment called CDR404 in patients with specific solid tumors. The study aims to evaluate its safety and effectiveness in fighting cancer.
We are testing a new medication, BHV-7000, to see if it can help reduce seizures in adults with refractory focal onset epilepsy. The study compares its effects to a placebo to evaluate safety and effectiveness.
We are studying a new treatment for people with idiopathic generalized epilepsy who have generalized tonic-clonic seizures. The trial will compare its effects to a placebo to see if it helps reduce seizure frequency and is safe to use.
We are evaluating the safety and tolerability of BHV-7000 in adults with refractory focal onset epilepsy. This study aims to ensure the treatment is safe for those who have not found relief with other options.
We are testing a new subcutaneous treatment for patients with Familial Chylomicronemia Syndrome who have previously used volanesorsen. The study aims to evaluate its safety and how well it is tolerated.
We are testing a new medication, lebrikizumab, to see if it helps adults with perennial allergic rhinitis experience fewer nasal symptoms. This study compares its effects to a placebo treatment.
We are studying a new ointment for people with generalized Epidermolysis Bullosa Simplex to see if it helps improve skin condition and reduce symptoms. The trial includes both adults and children aged 6 months and older.